Prevention of stroke associated with non-valvular atrial fibrillation

References

• 1. Ferro J.M. (2003) Cardioembolic stroke: an undate. Lancet Neurol., 2: 177–188.
• 2. Arboix A., Alio J. (2010) Cardioembolic stroke: clinical features, specific cardial disorders and prognosis. Curr. Сardio Rev., 6: 150.
• 3. Erikson S.E., Olsson J.E. (2001) Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Celebrovasc. Dis., 12(3): 171–180.
• 4. Kolominsky-Rabas P.L., Weber M., Gefeller O. et al. (2001) Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke, 32(12): 2735–2740.
• 5. Ferro J.M. (2003) Brain embolism. J. Neurol., 250: 139–147.
• 6. Murphy N.T., Simpson C.R., Jhund P.S. et al. (2007) A national survey of the prevalence, idence, prymari care burden and treatment of atrial fibrilation in Scotland. Heart, 93(5): 606–612. doi: 10.1136/hrt.2006.107573.
• 7. Hart R.G., Pearce L.A. (2009) Current status of stroke stratification in patients with atrial fibrillation. Stroke, 40: 2607–2610.
• 8. Roger V.L., Lloyd-Jones M.D. et al. (2012) Heart diases and statistics, 2012, update: a report from the American Heart association. Circulation, 125: e2–e220.
• 9. Wang T.J., Massaro J.M., Levy D. et al. (2003) A risk score predicting stroke or death in individuals with new — ouset atrial fibrilation in the community. JAMA, 290: 1049–1056.
• 10. Ezekowitz M.D., Connolly S., Parekh A. et al. (2009) Rationale and design of RE-LY: randomized evaluation of long term anticoagulant therapy, Warfarin, compared with Dabigatran. Am. Heart J., 157: 805–810.
• 11. Fuster V., Rydén L.E., Cannom D.S. et al. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 114(7): e257–e354.
• 12. Granger C.D., Alexander J.H., Memurray J.J. et al. (2011) Apixaban versus in nonvalvutar atrial fibrillation. N. Eng. J. Med., 365: 883–891.
• 13. Chiang Ch.-E., Wang K.-L., Lip G.Y.H. (2014) Stroke prevention in atrial fibrillation: an Asian perspective. Thromb. Haemost., 111(5): 789–797. doi: 10.1160/TH13-11-0948
• 14. Pister S.R., Lane D.A., Nieuwleat R. et al. (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 138: 1093–1100.
• 15. Aguilar M., Hart R., Pearcel L. (2007) Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst. Rev., 18: CD006186.
• 16. Aguilar M., Han R. (2005) Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transients ischemic attacks. Cochrane Database Syst. Rev., 20: CD001927.
• 17. Perzborn E., Roehrig S., Stranb A. et al. (2010) Rivarozaban: a new oral factor XA inhibitor. Arteriaseler. Thrombovasc. Biol., 30: 376–381.
• 18. https://compendium.com.ua/dec/261711/
• 19. Vehino K., Hernandez A.V. (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med., 172: 397–402.
• 20. Connolly S.J., Crigns H.J., Torp-Pedersen C. et al. (2009) Analysis of stroke in ATHENA: a placebo-controlled double-bring, parallee-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation, 120: 1174–1180.